PTCT - PTC Therapeutics GAAP EPS of -$2.66 misses by $1.04 revenue of $213.8M beats by $7.86M
2023-08-03 16:16:14 ET
- PTC Therapeutics press release ( NASDAQ: PTCT ): Q2 GAAP EPS of -$2.66 misses by $1.04 .
- Revenue of $213.8M (+28.8% Y/Y) beats by $7.86M .
- Cash, cash equivalents, and marketable securities was $337.9 million on June 30, 2023, compared to $410.7 million at December 31, 2022.
- PTC anticipates total revenues for the full year 2023 to be between $940 million and $1.0 billion.
- PTC anticipates net product revenues for the DMD franchise for the full year 2023 to be between $545 and $575 million.
- PTC anticipates GAAP R&D and SG&A expense for the full year 2023 to be between $930 million and $980 million.
For further details see:
PTC Therapeutics GAAP EPS of -$2.66 misses by $1.04, revenue of $213.8M beats by $7.86M